The enhanced BM homing capacity of Allo15CAR33-NKT/FG cells, likely driven by elevated CXCR4 and CCR5 expressions, underscores their potential therapeutic value for treating myeloid malignancies, particularly those involving refractory tumors located within the BM (Fig. 4j)4. This evidence concerns the gene CXCR4 and myeloid neoplasm.